As of close of business last night, Corcept Therapeutics Inc’s stock clocked out at $23.80, down -6.52% from its previous closing price of $25.46. In other words, the price has decreased by -$1.66 from its previous closing price. On the day, 818097 shares were traded.
Ratios:
To gain a deeper understanding of CORT’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.42. For the most recent quarter (mrq), Quick Ratio is recorded 4.31 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on November 06, 2023, Upgraded its rating to Buy and sets its target price to $38 from $29 previously.
On April 11, 2023, SVB Securities started tracking the stock assigning a Market Perform rating and target price of $25.
On April 04, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.Piper Sandler initiated its Overweight rating on April 04, 2023, with a $27 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 04 ’24 when Lyon Joseph Douglas sold 5,443 shares for $26.00 per share. The transaction valued at 141,524 led to the insider holds 7,314 shares of the business.
Swisher Daniel N JR sold 2,200 shares of CORT for $55,660 on Apr 01 ’24. The Director now owns 0 shares after completing the transaction at $25.30 per share. On Apr 01 ’24, another insider, Lyon Joseph Douglas, who serves as the insider of the company, sold 500 shares for $26.01 each. As a result, the insider received 13,004 and left with 7,314 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORT now has a Market Capitalization of 2.64B and an Enterprise Value of 2.27B. As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.11, and their Forward P/E ratio for the next fiscal year is 17.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.11 while its Price-to-Book (P/B) ratio in mrq is 4.86. Its current Enterprise Value per Revenue stands at 4.70 whereas that against EBITDA is 20.68.
Stock Price History:
Over the past 52 weeks, CORT has reached a high of $34.28, while it has fallen to a 52-week low of $20.87. The 50-Day Moving Average of the stock is 23.64, while the 200-Day Moving Average is calculated to be 26.51.
Shares Statistics:
It appears that CORT traded 1.39M shares on average per day over the past three months and 790.86k shares per day over the past ten days. A total of 103.41M shares are outstanding, with a floating share count of 89.26M. Insiders hold about 13.77% of the company’s shares, while institutions hold 80.32% stake in the company. Shares short for CORT as of Mar 15, 2024 were 20.22M with a Short Ratio of 15.29, compared to 19.64M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 19.53% and a Short% of Float of 31.38%.
Earnings Estimates
As of right now, 5 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.23 for the current quarter, with a high estimate of $0.29 and a low estimate of $0.19, while EPS last year was $0.14. The consensus estimate for the next quarter is $0.27, with high estimates of $0.35 and low estimates of $0.2.
Analysts are recommending an EPS of between $1.5 and $0.84 for the fiscal current year, implying an average EPS of $1.09. EPS for the following year is $1.38, with 4 analysts recommending between $1.48 and $1.25.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $140.8M. It ranges from a high estimate of $145.84M to a low estimate of $136M. As of the current estimate, Corcept Therapeutics Inc’s year-ago sales were $105.65M, an estimated increase of 33.30% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $150.69M, an increase of 37.40% over than the figure of $33.30% in the same quarter last year. There is a high estimate of $154.44M for the next quarter, whereas the lowest estimate is $146.44M.
A total of 5 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $621.95M, while the lowest revenue estimate was $600.14M, resulting in an average revenue estimate of $610.64M. In the same quarter a year ago, actual revenue was $482.38M, up 26.60% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $665.77M in the next fiscal year. The high estimate is $707.97M and the low estimate is $635M. The average revenue growth estimate for next year is up 9.00% from the average revenue estimate for this year.
